Most of us have been wrong short term about this stock. I

New Post Public Reply Private Reply Replies (0) Message Board
lodge
361
Most of us have been wrong short term about this stock. I think if we do not break the strong resistance at .75 the stock will not be able to stay in the trading range of .69,.70 - .75 and will drop like a rock. But even if that happens we are reaching the bottom and the stock will begin it's upward journey on good news.

I think it is a very risky play to sell now and get back in at .25, .20 or even lower. If the stock bounces and goes thru .75 you will want to jump out the window. This is what excites me about this business - my nature is Trader not Investor but I have been and will continue as an OWCP investor because of the Company's unusual potential and proximity to success.

OWCP is not owned by my trading account as my trading fingers could easily pull a sell - buy which is to risky a play at this stage. At 1.30 it probably would have been a smart move but that opportunity is gone.

I will add that I would not be a seller at 2,3,4,5 pps - when this stock finally makes a real move it should do much better than 2,3,etc.

OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links

OWCP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Exploring the Expansion of Data Diode Solutions Market Growth

Updated Category News Views 238

Understanding the Data Diode Solutions Market The Data Diode Solutions Market is rapidly evolving, with significant growth observed over recent years. This market is projected to increase from its current valuation of millions to an anticipated valuation surpassing USD 1.29 billion by the year 2033. This upward trajectory is driven by a compound annual growth rate (CAGR)...

Continue Reading
D.R. Horton Surpasses Expectations Amidst Housing Supply Crunch

Updated Category News Views 294

D.R. Horton Surpasses Revenue and Profit Expectations D.R. Horton has recently reported remarkable first-quarter results that exceeded analysts' expectations for both revenue and profit. This achievement comes in the context of a continuous shortage of existing homes in the U.S. housing market, which has significantly boosted the demand for new home sales, even amidst...

Continue Reading
Sustainable Innovations on the MS Mitsui Ocean Fuji Cruise Ship

Updated Category News Views 290

Introduction to the MS Mitsui Ocean Fuji The cruise industry is evolving, and the MS Mitsui Ocean Fuji, a remarkable vessel, is at the forefront of this change. This Japanese cruise ship, operated by Mitsui O.S.K. Lines, is an impressive example of how modern technology can meet sustainable practices in marine operations. History and Transition of the Ship Originally...

Continue Reading
South Korea's Trade Deal with U.S.: Seeking Rational Terms

Updated Category News Views 265

South Korea's Trade Deal Approaches Negotiation Hurdles In the world of international trade, negotiations can swing between promise and peril. Recently, the South Korean President Lee Jae Myung has raised significant concerns regarding a proposed trade deal with the United States, valued at $350 billion. This deal, originally discussed with former President Donald Trump,...

Continue Reading
Cullinan Therapeutics' CLN-049 Gains FDA Fast Track Approval

Updated Category News Views 141

Cullinan Therapeutics' New Milestone in Cancer Treatment Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, has recently received a significant boost in its fight against acute myeloid leukemia (AML). The U.S. Food and Drug Administration (FDA) has awarded Fast Track designation to its investigational drug CLN-049. This crucial milestone allows for...

Continue Reading